Product Pipeline

  • HP163 is ready for IND enabling pre-clinical development 
  • In-vivo studies in several cancer models show evidence of single agent efficacy and anti-tumor immune activation
  • Because HP163 blocks cancer via several patrhways at once, AhR inhibitors are set to become an important ingredient for many IO combination regimens. AhR inhibitors have already show synergy in combination with anti-PD(L)1 antibodies, IDO inhibitors, chemotherapy and BRAF inhibitors.
Hercules' AhR inhibitors are protected by composition of matter patents.